Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, usually aggressive malignant embryonal neoplasm of the central nervous system occurring in children. It is characterized by the presence of neuroepithelial cells which form papillary, trabecular, or tubular structures and absence of C19MC amplification. Symptoms include headache, nausea, and vomiting.
Biomarker and diagnostic research for medulloepithelioma has been reported in the published literature.
3 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
123 publications have been identified in PubMed for medulloepithelioma. Kisho has analyzed 97 by research type. Research spans Basic Science / Preclinical (42%), Review / Meta-Analysis (16%), and Gene Therapy / Novel Therapeutics (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 41 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
42%
Research summaries | 16 | 16% |
New treatment approaches | 15 | 15% |
Patient case studies | 12 | 12% |
Clinical study results | 5 | 5% |
Testing and diagnosis research | 4 | 4% |
Disease patterns and progression | 3 | 3% |
Other research | 1 | 1% |
Nazam N (2026). [PMID: 41539997](https://pubmed.ncbi.nlm.nih.gov/41539997/). *Cell Death Dis*. [Basic Science / Preclinical]
Wang L (2026). [PMID: 41285250](https://pubmed.ncbi.nlm.nih.gov/41285250/). *Mod Pathol*. [Diagnostic / Biomarker]
Bernardi F (2026). [PMID: 41544627](https://pubmed.ncbi.nlm.nih.gov/41544627/). *Cancer Cell*. [Basic Science / Preclinical]
Radke K (2026). [PMID: 41437160](https://pubmed.ncbi.nlm.nih.gov/41437160/). *EMBO Mol Med*. [Gene Therapy / Novel Therapeutics]
Tauziède-Espariat A (2026). [PMID: 41817752](https://pubmed.ncbi.nlm.nih.gov/41817752/). *Virchows Arch*. [Case Report / Case Series]
Zhou H (2026). [PMID: 41213462](https://pubmed.ncbi.nlm.nih.gov/41213462/). *Cancer Lett*. [Basic Science / Preclinical]
Angulo Velásquez J (2026). [PMID: 42177983](https://pubmed.ncbi.nlm.nih.gov/42177983/). *Arch Soc Esp Oftalmol (Engl Ed)*. [Case Report / Case Series]
Asghar E (2026). [PMID: 41401403](https://pubmed.ncbi.nlm.nih.gov/41401403/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Meng Y (2026). [PMID: 42053483](https://pubmed.ncbi.nlm.nih.gov/42053483/). *Ophthalmol Retina*. [Case Report / Case Series]
Werr L (2026). [PMID: 41678281](https://pubmed.ncbi.nlm.nih.gov/41678281/). *J Clin Invest*. [Gene Therapy / Novel Therapeutics]